NNMT Inhibitor Program

About Ridgeline Therapeutics

Ridgeline Therapeutics is a private, preclinical-stage biotech pioneering a novel therapeutic approach by inhibiting the NNMT enzyme. The company's platform aims to address multiple major chronic diseases linked to dysregulated cellular metabolism and epigenetic pathways through once-daily oral drugs. Led by a scientifically experienced founding team and supported by a seasoned business advisory board, Ridgeline is advancing its lead candidates toward clinical development in large, underserved markets.

About Cantoni Therapeutics

Cantoni Therapeutics is an early-stage biotech developing a novel class of bisubstrate small molecule inhibitors against the enzyme NNMT, a target implicated in metabolic dysregulation and cancer. The company's lead programs are in pre-clinical development for cardiometabolic disorders, aiming to address root causes of conditions like type 2 diabetes and obesity where current treatments often fall short. Founded in 2021 and based in Amsterdam, Cantoni is a private, pre-revenue company building a management team and advancing its proprietary platform.

Therapeutic Areas